Rigel Pharmaceuticals secures global rights to develop and commercialize VEPPANU

Rigel Pharmaceuticals secures global rights to develop and commercialize VEPPANU
Rigel signs VEPPANU deal

Rigel Pharmaceuticals today announced it has entered into an exclusive, global license agreement to develop, manufacture and commercialize VEPPANU, also known as vepdegestrant.

The company plans to advance the development of VEPPANU through this agreement and pursue worldwide commercialization opportunities. Investors and stakeholders can review further details in the official press release and listen to a webcast scheduled for today at 5:00 am ET.

Rigel Pharmaceuticals recently confirmed it will release Q1 2026 financial results and a business update on May 5. The scheduled update follows the company’s ongoing development and licensing activities. Financial performance and pipeline progress will be covered during that announcement.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.